Tirofiban Combined with Fondaparinux for Post-PCI Treatment of Patients with Acute Coronary Syndrome and Mild Renal Insufficiency.
Proper administration of antithrombotic and antiplatelet drugs after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) and renal insufficiency is a challenging task. In this study, we utilized Fondaparinux and Tirofiban (either separately or combined) to treat post-PCI patients with ACS and concurrent renal insufficiency. The patients were followed-up for 1 year. We observed that combined treatment led to a higher number of significant therapeutic effects and better reduced the frequency of bleeding events. Our findings indicate that combined antithrombotic and antiplatelet treatment improves the prognosis in patients with ACS and renal insufficiency who received PCI treatment.
Department of Cardiology, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, 510010, People's Republic of China. drhongchangjiang@163.com.
Hong
H
Changjiang
Department of Cardiology, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, 510010, People's Republic of China.
Qiu
Q
Jian
Department of Cardiology, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, 510010, People's Republic of China.
Zhang
Z
Yuan
Department of Cardiology, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, 510010, People's Republic of China.
Yang
Y
Liang
Department of Cardiology, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, 510010, People's Republic of China.
Lin
L
Puqing
Department of Cardiology, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, 510010, People's Republic of China.
Gu
G
Xiaolong
D054058:Acute Coronary Syndrome / Q000150:complications / Q000188:drug therapy / Q000601:surgery*; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D000077425:Fondaparinux; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects*; D011134:Polysaccharides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000188:drug therapy / Q000517:prevention & control*; D051437:Renal Insufficiency / Q000150:complications*; D000077466:Tirofiban; D014443:Tyrosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000925:Anticoagulants; D004338:Drug Combinations; D011134:Polysaccharides; D014443:Tyrosine; D000077466:Tirofiban; D000077425:Fondaparinux
Acute coronary syndrome; Fondaparinux; Percutaneous coronary intervention; Renal insufficiency; Tirofiban